NRG-LU002

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC):  A Randomized Phase II/III Trial

Principal Investigator

Puneeth Iyengar, MD PhD

Status

Closed to Accrual

Disease Site

Lung [LU]

Non-small Cell Lung Cancer

Phase

II/III

Developmental Therapeutics

No

Primary Objective

Phase II: To evaluate the impact of adding LCT (local consolidative therapy) to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy

Phase III: To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy 

Patient Population

Metastatic non-small cell lung cancer (NSCLC) patients who have 3 or fewer metastatic sites (excluding primary) and exhibit at least stable disease after four cycles of first line/induction systemic therapy.

Target Accrual

400